These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 11733394)
1. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Baran KW; Nguyen M; McKendall GR; Lambrew CT; Dykstra G; Palmeri ST; Gibbons RJ; Borzak S; Sobel BE; Gourlay SG; Rundle AC; Gibson CM; Barron HV; Circulation; 2001 Dec; 104(23):2778-83. PubMed ID: 11733394 [TBL] [Abstract][Full Text] [Related]
2. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. Faxon DP; Gibbons RJ; Chronos NA; Gurbel PA; Sheehan F; J Am Coll Cardiol; 2002 Oct; 40(7):1199-204. PubMed ID: 12383565 [TBL] [Abstract][Full Text] [Related]
3. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study. Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719 [TBL] [Abstract][Full Text] [Related]
4. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). Di Mario C; Bolognese L; Maillard L; Dudek D; Gambarati G; Manari A; Guiducci V; Patrizi G; Rusconi LC; Piovaccari G; Hibon AR; Belpomme V; Indolfi C; Olivari Z; Steffenino G; Zmudka K; Airoldi F; Panzarasa R; Flather M; Steg PG Am Heart J; 2004 Sep; 148(3):378-85. PubMed ID: 15389222 [TBL] [Abstract][Full Text] [Related]
5. Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group. Rhee P; Morris J; Durham R; Hauser C; Cipolle M; Wilson R; Luchette F; McSwain N; Miller R J Trauma; 2000 Oct; 49(4):611-9; discussion 619-20. PubMed ID: 11038077 [TBL] [Abstract][Full Text] [Related]
6. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E; Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099 [TBL] [Abstract][Full Text] [Related]
7. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Ohman EM; Kleiman NS; Gacioch G; Worley SJ; Navetta FI; Talley JD; Anderson HV; Ellis SG; Cohen MD; Spriggs D; Miller M; Kereiakes D; Yakubov S; Kitt MM; Sigmon KN; Califf RM; Krucoff MW; Topol EJ Circulation; 1997 Feb; 95(4):846-54. PubMed ID: 9054741 [TBL] [Abstract][Full Text] [Related]
8. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Rusnak JM; Kopecky SL; Clements IP; Gibbons RJ; Holland AE; Peterman HS; Martin JS; Saoud JB; Feldman RL; Breisblatt WM; Simons M; Gessler CJ; Yu AS Am J Cardiol; 2001 Sep; 88(5):482-7. PubMed ID: 11524054 [TBL] [Abstract][Full Text] [Related]
9. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Van de Werf F; Arnold AE BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. Allison DE; Gourlay SG; Koren E; Miller RM; Fox JA BioDrugs; 2002; 16(1):63-70. PubMed ID: 11968154 [TBL] [Abstract][Full Text] [Related]
11. Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Willems JL; Willems RJ; Willems GM; Arnold AE; Van de Werf F; Verstraete M Circulation; 1990 Oct; 82(4):1147-58. PubMed ID: 2119263 [TBL] [Abstract][Full Text] [Related]
13. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Gibson CM; Murphy SA; Morrow DA; Aroesty JM; Gibbons RJ; Gourlay SG; Barron HV; Giugliano RP; Antman EM; Braunwald E Am Heart J; 2004 Aug; 148(2):336-40. PubMed ID: 15309006 [TBL] [Abstract][Full Text] [Related]
14. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study. Wong A; Mak KH; Chan C; Koh TH; Lau KW; Lim TT; Lim ST; Wong P; Sim LL; Lim YT; Tan HC; Lim YL Catheter Cardiovasc Interv; 2004 Aug; 62(4):445-52. PubMed ID: 15274152 [TBL] [Abstract][Full Text] [Related]
15. ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy). Cura FA; Roffi M; Pasca N; Wolski KE; Lincoff AM; Topol EJ; Lauer MS; Am J Cardiol; 2004 Oct; 94(7):859-63. PubMed ID: 15464665 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings. Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Pu J; Ding S; Ge H; Han Y; Guo J; Lin R; Su X; Zhang H; Chen L; He B; Circulation; 2017 Oct; 136(16):1462-1473. PubMed ID: 28844990 [TBL] [Abstract][Full Text] [Related]
18. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count. Vrachatis AD; Alpert MA; Georgulas VP; Nikas DJ; Petropoulou EN; Lazaros GI; Michelakakis NA; Karavidis AI; Lakoumentas JA; Stergiou L; Zacharoulis AA Angiology; 2001 Mar; 52(3):161-6. PubMed ID: 11269778 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Vanderschueren S; Barrios L; Kerdsinchai P; Van den Heuvel P; Hermans L; Vrolix M; De Man F; Benit E; Muyldermans L; Collen D Circulation; 1995 Oct; 92(8):2044-9. PubMed ID: 7554180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]